A Phase 4 interventional study of Liraglutide in Obesity and HIV Infections, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in South Africa. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-31.
Sponsored by Brigham and Women's Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.
Among the 79 studies testing liraglutide in Obesity, this one is the 52nd largest by planned enrollment, is one of 2 that started in 2024, is one of 37 in phase 4, and was the 75th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Affiliated Hospital of Nantong University · Sites in China
Ages 18–70
Emirates Health Services (EHS) · Sites in United Arab Emirates
Ages 22–60 · Healthy volunteers
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–75
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 18 · Phase 4 37
First in 2007; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 70 across the 79 interventional studies. Of the 54 that completed or were terminated, 24 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 79 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
38 studies in Obesity by Brigham and Women's Hospital: 7 open now, 15 under way, none of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 38 studies in Obesity by Brigham and Women's Hospital, this one is the 18th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2024, is one of 4 in phase 4, reaches primary completion later than 3 of the 14 other live ones, and was the 34th registered.
Brigham and Women's Hospital’s Obesity studies by the year they started, since 1976.
2 of the studies testing liraglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT02944500Beth Israel Deaconess Medical CenterSaxenda: Underlying Mechanisms and Clinical Outcomes | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies testing liraglutide in Obesity, from their registry updates:
Among Brigham and Women's Hospital’s 38 in Obesity:
This tab as a report to print or save as PDF → With an account.
The goal of this single-arm, open label pilot study is to evaluate liraglutide at the recommended dosage administered subcutaneously + lifestyle counselling for the management of people living with HIV (PLWH) with obesity defined by a BMI ≥30 kg/m2 who are on dolutegravir-based ART.
Following individual informed consent, all participants will undergo a series of basic cardiometabolic labs. They will then be initiated on liraglutide 0.6 mg administered subcutaneously, and this dose will be gradually increased over a period of 4 weeks to a dose of 3.0 mg daily. Alongside drug administration, participants will receive lifestyle counselling regarding diet and physical activity. Following completion of a 12-week "on treatment" period, liraglutide will be stopped and participants will be followed for an additional 12-weeks off treatment. Body weight, cardiometabolic risk parameters, and a suite of patient-reported outcomes regarding diet, physical activity, sleep, and quality of life will be assessed periodically over the course of the study.
South Africa has the largest population of PLWH globally, with a prevalence of 17% in adults or 7.2 million PLWH. The rapid scale-up of ART programs has resulted in >6 million PLWH on treatment, significant gains in life expectancy, and a large population of aging PLWH. With increasing life expectancy, obesity and type 2 diabetes have become growing threats for PLWH in South Africa and globally. One recent study found that 63% of PLWH are overweight or obese, and 6% have diabetes in this setting.
This elevated risk of obesity in PLWH in South Africa is likely due to a confluence of both general considerations and HIV-specific factors. First, South Africa has experienced an accelerated background epidemic of metabolic disease in the general population with a prevalence of overweight and obesity that is nearly equal to that of high-income countries. Additionally, the International Diabetes Federation estimates that approximately 15.5 million adults are living with diabetes in the African Region, and projects it to grow to 41 million by 2045. As part of this background epidemic of metabolic disease, South Africa is also experiencing a nutrition transition, with widespread availability of processed and refined foods as well as sugar-sweetened beverages.
Regarding HIV-specific issues, in 2019 the first-line ART regimen for the South African national HIV treatment program transitioned to TLD. TLD is generally very safe and well-tolerated and has a high barrier to HIV resistance but this transition to this regimen has been associated with risk of excess weight gain at the population level. Both clinical trials and observational studies conducted in South Africa have shown substantial increases in body weight in those who are initiating this ART regimen newly and among those who are suppressed and switched, especially women. Given this, there is a growing risk of obesity in PLWH in this context and a need for management strategies to address this increasingly prevalent comorbidity.
Preventing the metabolic complications of HIV in South Africa and worldwide requires urgent solutions. To date, obesity management and diabetes prevention have largely consisted of behavioural interventions such as the Diabetes Prevention Program and related lifestyle modification efforts, focused on improving diet and increasing physical activity. However, in the past several years, novel anti-obesity pharmacologic agents such as the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown enormous promise for obesity management and diabetes prevention in people who are HIV-negative (8-10). However, this drug class has a very limited evidence base in PLWH and relatively scant data from sub-Saharan African populations.
Currently, liraglutide is the only GLP-1 RA approved for obesity management in South Africa and this protocol proposes to use the drug for its labelled indication of "weight loss in addition to diet and exercise in adults aged 18 and above who have: (1) a BMI of 30 or greater (obese) or (2) a BMI of greater than 27 and less than 30 (overweight) and weight related health problems (such as diabetes, high blood pressure, hypercholesterolemia, or obstructive sleep apnoea).
This evidence gap motivates further inquiry into GLP-1 RAs such as liraglutide as one potential approach to obesity management and prevention of diabetes in PLWH who have comorbid obesity in South Africa, with implications for PLWH in other contexts. In this proposal, the investigators seek to further this important area of inquiry by evaluating the acceptability of liraglutide along with lifestyle counselling in PLWH who have obesity and are stable on dolutegravir-based ART in South Africa.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following individual informed consent, all participants will undergo a series of basic cardiometabolic labs. They will then be initiated on liraglutide 0.6 mg administered subcutaneously, and this dose will be gradually increased over a period of 4 weeks to a dose of 3.0mg daily. Alongside drug administration, participants will receive lifestyle counselling regarding diet and physical activity. Following completion of a 12-week "on treatment" period, liraglutide will be stopped and participants will be followed for an additional 12-weeks off treatment. Body weight, cardiometabolic risk parameters, and a suite of patient-reported outcomes regarding diet, physical activity, sleep, and quality of life will be assessed periodically over the course of the study.
Drug: Liraglutide
Dosing regimen: In this study protocol, liraglutide dosing will be implemented as follows: Liraglutide will be started at a dose of 0.6 mg per day. Participants will be taught to use the injection pen and will be observed giving the first injection. The dose will then be increased by 0.6 mg each week to a maximum dosage of 3.0 mg per day at the end of 4 weeks. This corresponds to the following dosing schedule: Week 1: 0.6 mg per day for one week Week 2: 1.2 mg per day for one week Week 3: 1.8 mg per day for one week Week 4: 2.4 mg per day for one week Week 5-12: 3.0 mg per day for 8 weeks Week 13-24: No drug administration
Also known as: Saxenda
Proportion of participants who screen and enroll among those approached
This will be expressed in terms of the proportion of participants who attend screening and enrolment visits among the total number who are approached regarding interest in study participation.
Time frame: Measured at screening
Time to reach study enrollment target
Time frame: Measured at enrollment
Study retention rate at 12 weeks
This will be expressed as a proportion of participants who remain in the study after the 12 week "on treatment" period among those enrolled.
Time frame: Measured at Visit 4 at 12 weeks
Study retention rate at 24 weeks
This will be expressed as a proportion of participants who remain in the study after the full 24 weeks of study procedures are completed among those enrolled.
Time frame: Measured at End of Study at 24 weeks
Rate of adherence to treatment over 12 weeks
The investigators will assess volume remaining in the injector pens and provide a percentage of doses per participant that remained unused at the end of the 12-week period on treatment.
Time frame: Measured at Visit 4 at 12 weeks
Embedded qualitative interviews regarding the acceptability of liraglutide for obesity management
This will be open-ended responses to a brief exit interview about acceptability and feasibility.
Time frame: Measured at End of Study at 24 weeks
Incidence of treatment-emergent adverse events as defined in this protocol
The investigators will report incidence of TEAEs up to 24 weeks (12 weeks on + 12 weeks off treatment)
Time frame: From the initiation of treatment until the date of a treatment-emergent adverse event, assessed up to 24 weeks.
Incidence of serious adverse events (SAEs), as defined in this protocol
The investigators will report incidence of SAEs up to 24 weeks (12 weeks on + 12 weeks off treatment)
Time frame: From the initiation of treatment until the date of a serious adverse event, assessed up to 24 weeks.
Change in body weight following 12 weeks on treatment
Body weight will be measured in the study at both enrolment and after 12 weeks on treatment (Visit 4); these will be used to calculate a continuous change in kg.
Time frame: Measured at Visit 4 at 12 weeks
Change in body weight over 24 weeks (12 weeks on + 12 weeks off treatment)
Body weight will be measured in the study at both enrolment and after 24 weeks on treatment (EOS); these will be used to calculate a continuous change in kg.
Time frame: Measured at End of Study at 24 weeks
Change in HbA1c following 12 weeks on treatment
HbA1c will be measured at enrolment and at Visit 4; here investigators will calculate the difference between these measures (in %).
Time frame: Measured at Visit 4 at 12 weeks
Change in HbA1c over 24 weeks (12 weeks on + 12 weeks off treatment)
HbA1c will be measured at enrolment and at EOS; here investigators will calculate the difference between these measures (in %).
Time frame: Measured at End of Study at 24 weeks
Change in fasting plasma glucose following 12 weeks on treatment
Fasting glucose will be measured at enrolment and at Visit 4; investigators will calculate the difference between these measures (in mmol/L).
Time frame: Measured at Visit 4 at 12 weeks
Change in fasting plasma glucose over 24 weeks (12 weeks on + 12 weeks off treatment)
Fasting glucose will be measured at enrolment and at EOS; investigators will calculate the difference between these measures (in mmol/L).
Time frame: Measured at End of Study at 24 weeks
Change in depressive symptoms following 12 weeks on treatment
This will be defined as the difference in depression score per the Patient Health Questionnaire (PHQ-9) at enrolment and Visit 4. The minimum value is 1 and the maximum is 27, where the greater the total score, the greater severity of depression.
Time frame: Measured at Visit 4 at 12 weeks
Change in depressive symptoms over 24 weeks (12 weeks on + 12 weeks off treatment)
This will be defined as the difference in depression score per the Patient Health Questionnaire (PHQ-9) at enrolment and EOS. The minimum value is 1 and the maximum is 27, where the greater the total score, the greater severity of depression.
Time frame: Measured at End of Study at 24 weeks
Change in physical activity level following 12 weeks on treatment
This will be defined as the difference in physical activity expressed in MET-minutes per week, where MET minutes represent the amount of energy expended carrying out physical activity, per the International Physical Activity Questionnaire (IPAQ) at enrolment and Visit 4.
Time frame: Measured at Visit 4 at 12 weeks
Change in physical activity level over 24 weeks (12 weeks on + 12 weeks off treatment)
This will be defined as the difference in physical activity expressed in MET-minutes, where MET minutes represent the amount of energy expended carrying out physical activity, per week per the International Physical Activity Questionnaire (IPAQ) at enrolment and EOS.
Time frame: Measured at End of Study at 24 weeks
Change in dietary habits following 12 weeks on treatment
This will be defined as the difference in total servings of fruits and vegetables, change in frequency of sugar-sweetened beverage intake, and change frequency of fast food intake from enrolment to Visit 4.
Time frame: Measured at Visit 4 at 12 weeks
Change in dietary habits over 24 weeks (12 weeks on + 12 weeks off treatment)
This will be defined as the difference in total servings of fruits and vegetables, change in frequency of sugar-sweetened beverage intake, and change frequency of fast food intake from enrolment to EOS.
Time frame: Measured at End of Study at 24 weeks
Change in blood pressure following 12 weeks on treatment
Systolic blood pressure change in mm Hg
Time frame: Measured at Visit 4 at 12 weeks
Change in blood pressure over 24 weeks (12 weeks on + 12 weeks off treatment)
Blood pressure change in mm Hg
Time frame: Measured at End of Study at 24 weeks
Change in lipids following 12 weeks on treatment
Change in total cholesterol
Time frame: Measured at Visit 4 at 12 weeks
Change in lipids over 24 weeks (12 weeks on + 12 weeks off treatment)
Change in total cholesterol
Time frame: Measured at End of Study at 24 weeks
Change in waist circumference following 12 weeks on treatment
Change in waist circumference in cm
Time frame: Measured at Visit 4 at 12 weeks
Change in waist circumference over 24 weeks (12 weeks on + 12 weeks off treatment)
Change in waist circumference in cm
Time frame: Measured at End of Study at 24 weeks
Change in quality of life following 12 weeks on treatment per the World Health Organization's Quality of Life Instrument in HIV Infection
Change in quality of life scale score (scale of 0 - 100)
Time frame: Measured at Visit 4 at 12 weeks
Change in quality of life over 24 weeks (12 weeks on + 12 weeks off treatment) per the World Health Organization's Quality of Life Instrument in HIV Infection
Change in quality of life scale score (scale of 0 - 100)
Time frame: Measured at End of Study at 24 weeks
Change in sleep quality following 12 weeks on treatment per the Pittsburgh Sleep Quality Index
Change in sleep quality scale score (global score range of 0 to 21 where score of 5 or greater indicates poor sleep)
Time frame: Measured at Visit 4 at 12 weeks
Change in sleep quality over 24 weeks (12 weeks on + 12 weeks off treatment) per the Pittsburgh Sleep Quality Index
Change in sleep quality scale score (global score range of 0 to 21 where score of 5 or greater indicates poor sleep)
Time frame: Measured at End of Study at 24 weeks
Plan to share: Yes — Anonymized data as allowable
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: The IPD data will be shared in accordance with AHRI Data Access Policy and Data Management Plan within two years of completion.
Access criteria: Access to the IPD and the associated documents will require completion of the online data access application form accessible on the AHRI Data repository. AHRI bona fide data users are required to abide by the data use conditions stipulated on the application for access to the data.
Data sharing details ↗ · data.ahri.org
Started May 2024 (actual). Primary completion is estimated for May 2025, 12 months after the start.
Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 12 months is below that.
Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide
Brigham and Women's Hospital →